NPS Pharmaceuticals (NPSP)
News
| May 24 | $NPSP Wonder if this spike has anything to do with CHMP decision? by Random_Walk |
| May 24 | $NPSP by Random_Walk |
| May 23 | RT @TheEquitiesRoom: EBR: Watchlist/worksheet/4 Trading Ideas: $DECK $CRR $NPSP $LOW $V http://stks.co/3wzM < thanks for sharing by 1nvestor |
| May 23 | EBR: Watchlist/worksheet/4 Trading Ideas: $DECK $CRR $NPSP $LOW $V http://stks.co/3wxm by TheEquitiesRoom |
| May 21 | $NPSP Close at highs, nice volume too. Can't figure out why this isn't getting more attention. by Random_Walk |
| May 18 | $NPSP Inside day on decent volume. Higher we go. by Random_Walk |
| May 18 | $NPSP Nice rebound today after yesterday's selloff. Good volume for a change. by Random_Walk |
| May 17 | [video] Stocks Under $10: Healthcare Name on Sale |
| May 15 | $NPSP http://stks.co/3pss Golden Cross, 50MA cross above the 200MA, breakingout the $7.39 resistance, positive momentum by gantosj |
| May 14 | $NPSP $AKRX Strong today in an ugly tape. by Random_Walk |
| May 07 | On The Fly: Analyst Initiation Summary |
| May 07 | Canaccord Genuity Starts NPS Pharmaceuticals Inc. (NPSP) at Buy Street Insider |
| May 07 | NPS Pharmaceuticals coverage assumed with a Buy at Canaccord |
| May 04 | Needham & Company Reiterates a 'Buy' on NPS Pharmaceuticals (NPSP); Awaiting Date for... |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
NPS Pharmaceuticals, Inc. engages in the discovering, developing and commercializing small molecule drugs and recombinant proteins. Its existing product candidates are primarily for the treatment of bone and mineral, gastrointestinal and central nervous system disorders. The company is currently advancing two late-stage programs. Teduglutide, a proprietary analog of glucagon and preclinical development for additional intestinal failure related conditions. NPSP558 is a clinical development as a hormone therapy for hypoparathyroidism. Its product portfolio consists of a United States Food and Drug Administration approved product, as well as product candidates in various stages of clinical development and preclinical development. NPS Pharmaceuticals, Inc. was founded on October 22, 1986 and is based in Bedminster, New Jersey.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). NPS Pharmaceuticals is down 20.27% over the last year vs S&P 500 Total Return up 2.03%, Immunomedics down 19.76%, and Arena Pharmaceuticals up 308.2%.
- NPSP Total Returns
- ^SPXTR Total Returns
- IMMU Total Returns
- ARNA Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these NPSP related companies
Pro Strategies Featuring NPSP
Did NPS Pharmaceuticals make it into our Pro Portfolio Strategies?
NPSP Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other NPSP Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NPSP | 7.59 | -0.26 | -3.31% | 653.57M |
| NPM | 15.24 | +0.03 | +0.20% | |
| NPD | 2.62 | -0.05 | -1.87% | 270.20M |
| NPBC | 8.80 | -0.05 | -0.56% | 1.340B |
| NOK | 2.82 | +0.08 | +2.92% | 10.56B |
| NNBR | 7.82 | -0.21 | -2.62% | 132.55M |
| NNA | 2.599 | -0.01 | -0.41% | 105.32M |
| NMR | 3.21 | -0.03 | -0.93% | 11.76B |
| NMM | 13.91 | +0.82 | +6.26% | 652.24M |
| NJ | 19.93 | +0.07 | +0.35% | 11.57B |
